

Genomics as an Informational Tool in Neurorehabilitation

Steven C. Cramer, MD

Professor, Depts. Neurology, Anatomy & Neurobiology, and PM&R
Associate Director, Institute for Clinical & Translational Science
Co-PI, NIH StrokeNet (Recovery & Rehabilitation)

University of California, Irvine

Disclosures

Dr. Cramer serves as a consultant for MicroTransponder, Dart Neuroscience, Roche, Neuroolutions, Regenera, Abbvie, SanBio, and TRCare.

Genetics and Stroke Recovery/Rehab

Types of genetic variation

Stroke recovery, neurorehabilitation, and neural plasticity

Genetic variation in relation to recovery, rehab, and plasticity

Types of genetic variation

Stroke recovery, neurorehabilitation, and neural plasticity

Genetic variation in relation to recovery, rehab, and plasticity

Genetics--what are the variables?

Human DNA

23 pairs of chromosomes
~6.3 billion base pairs
~20,000 protein-encoding genes

Alleles

Different forms of the same gene [*Color blindness*]
Generally, each person has 2 alleles for a given gene

Classifying genetic variation

Genetic mutation: rare, causes signif functional change [*HD*]

Genetic polymorphism: not rare (frequency $\geq 1\%$), relatively small effect on behavior or phenotype [*blood type*]

Many types of polymorphism, e.g., single nucleotide polymorphisms (SNP) [*BDNF val⁶⁶met*], variable number of tandem repeats, insertions/deletions, etc

Numerous classes of genetic variation, e.g., can have translocations of large amounts of DNA, frameshift, copy number variations

Epigenetics: changes in the regulation of gene activity and

Understanding genetic variation via interactions

Interaction with another gene

Epistasis: when the expression of one gene is modified by another gene

Understanding genetic variation via interactions

Interaction with another gene

Epistasis: when the expression of one gene is modified by another gene

Interaction with chemical state

Genome-Wide Variant by Serum Urate Interaction in Parkinson's Disease

Arash Nazari, MD,^{1,2} Tara Rostami, MD, MPH,^{1,2} Shokufah Sadeghian, MD,¹
M. Mulla Chaturvedi, PhD,^{1,2} Shirley Eberly, MS,¹
Anthony E. Lang, MD, FRCPC, FAHA,^{1,2}
and Annette N. Vowles, MD, PhD, FRCPC,^{1,2,3,4}

Objective: Serum urate levels have been associated with risk for onset and progression of Parkinson's disease (PD). Some related compounds are thought to contribute to neuroprotective effects by some PD progression. It is interesting to explore a possible causal interaction as a genetic disease-modifying effect in people with PD. However, PD is heterogeneous disease, and genetic studies may require stratification. **Design:** Genetic and epidemiologic data were used to explore a genetic modification effect in people with PD. **Methods:** We conducted a genome-wide association study to identify gene variants in serum urate interaction with PD in the Genetic Epidemiology of Parkinson's Disease Study. **Results:** We identified a genome-wide association study (GWAS) signal at 10q24.33, near the *PPP4R2* gene, associated with PD in people with PD. **Conclusion:** We identified a genome-wide association study (GWAS) signal at 10q24.33, near the *PPP4R2* gene, associated with PD in people with PD. **Keywords:** Parkinson's disease, serum urate, genetic variation, interaction, PD, GWAS, *PPP4R2*.

Understanding genetic variation via interactions

Interaction with another gene

Epistasis: when the expression of one gene is modified by another gene

Interaction with chemical state

Interaction with experience

Smoking and Parkinson disease

Evidence for gene-by-smoking interactions

Yu Chen, MD, PhD,¹ Ronald Brown, PhD,² Markku Aho, MD, PhD,³ David M. Kaye, PhD, Kimberly C. Paul, PhD,⁴ W. H. Rossor, MD, PhD,⁵ Bruce Hil, MD, PhD,⁶ and Anne E. Sklar, MD, PhD,¹
*Correspondence: sklar@u.washington.edu

Genome-Wide Variant by Serum Urate Interaction in Parkinson's Disease

Arash Nazari, MD,^{1,2} Tara Rostami, MD, MPH,^{1,2} Shokufah Sadeghian, MD,¹
M. Mulla Chaturvedi, PhD,^{1,2} Shirley Eberly, MS,¹
Anthony E. Lang, MD, FRCPC, FAHA,^{1,2}
and Annette N. Vowles, MD, PhD, FRCPC,^{1,2,3,4}

Objective: Serum urate levels have been associated with risk for onset and progression of Parkinson's disease (PD). Some related compounds are thought to contribute to neuroprotective effects by some PD progression. It is interesting to explore a possible causal interaction as a genetic disease-modifying effect in people with PD. However, PD is heterogeneous disease, and genetic studies may require stratification. **Design:** Genetic and epidemiologic data were used to explore a genetic modification effect in people with PD. **Methods:** We conducted a genome-wide association study to identify gene variants in serum urate interaction with PD in the Genetic Epidemiology of Parkinson's Disease Study. **Results:** We identified a genome-wide association study (GWAS) signal at 10q24.33, near the *PPP4R2* gene, associated with PD in people with PD. **Conclusion:** We identified a genome-wide association study (GWAS) signal at 10q24.33, near the *PPP4R2* gene, associated with PD in people with PD. **Keywords:** Parkinson's disease, serum urate, genetic variation, interaction, PD, GWAS, *PPP4R2*.

Approaches to studying genetic association

- Candidate gene approach, examines key genes
- Genome-wide association study, assesses massive # polymorphisms
- Gene score, examines group of genes across one system
- Many other possible approaches, e.g., exome sequencing, epigenetics, transcriptomic variation

Types of genetic variation

Stroke recovery, neurorehabilitation, and neural plasticity

Genetic variation in relation to recovery, rehab, and plasticity

What is stroke recovery, rehabilitation, and neural plasticity ?

Potential human restorative therapies

- **Small molecules** eg, SSRIs, amphetamine, levodopa, niacin, memantine, etc
- **Growth factors** eg, EPO, hCG, G-CSF, b-FGF, OP-1, etc
- **Monoclonal Ab**, other large molecules eg, anti-MAG Ab
- **Stem cells**
- **Brain stimulation** eg, TMS, tDCS, tACS, epidural stim, deep brain stim; vagal nerve stim
- **Telemedicine**
- **Intensive physiotherapy, robotics, other training**
- **Lesion bypass** eg, BCI, nerve transfer
- **Motor imagery, observation, environmental enrichment, other cognitive Rx**

What is stroke recovery, rehabilitation, and neural plasticity ?

Use of these terms is usually far too broad for their measurement to connect with specific gene-based hypotheses.

What is stroke recovery, rehabilitation, and neural plasticity ?

Use of these terms is usually far too broad for their measurement to connect with specific gene-based hypotheses.

Molecular
Systems
Behavior

Cellular & molecular events underlying stroke recovery

Ipsilesional changes

- ↑ inflammatory markers
- ↑ growth-associated proteins
- ↑ cell cycle proteins
- ↑ growth factors
- GABA receptor downregulation
- ↑ NMDA receptor binding
- angiogenesis
- hyperexcitability & facilitation of LTP
- synaptogenesis
- ↓ dendrite branching/spine density
- ↓ neuronal sprouting
- extracellular matrix remodelling
- ↓ cortical thickness


Contralesional changes

- ↑ inflammatory markers
- ↑ growth-associated proteins
- GABA receptor downregulation
- ↑ NMDA receptor binding
- neuronal hyperexcitability
- ↑ dendrite br/spine density
- synaptogenesis
- ↑ cortical thickness

Molecular
Systems
Behavior

Cramer & Chopp, *TINS* 00; Wieloch & Nikolich, *Curr Op Nbio* 06; Carmichael, *Ann Neurol* 16


Laterality of brain function and stroke recovery



Molecular
Systems
Behavior







Cramer et al, *Stroke*. 1997; 28:2518-2527.

Laterality of brain function and stroke recovery



Less lateralized (more bilaterally organized) with larger infarct worse deficits over time non-dominant side infarct

Cramer et al, *Stroke* 97; Marshall et al, *Stroke* 00; Cramer et al, *Exp Br Res* 05



Behavioral recovery after stroke

The Case for Modality-Specific Outcome Measures in Clinical Trials of Stroke Recovery-Promoting Agents

Steven C. Cramer, MD; Walter J. Koroshetz, MD; Seth P. Finklestein, MD

Stroke. 2007;38:1393-1395.

Types of genetic variation

Stroke recovery, neurorehabilitation, and neural plasticity

Genetic variation in relation to recovery, rehab, and plasticity

REVIEW

 The influence of genetic factors on brain plasticity and recovery after neural injury

Karin M. Pearson-Fuhrhop¹, Eric Baska², and Steven C. Cramer^{1*}

Curr Opin Neurol 2012, 25:682-688

Genetics as a molecular window into recovery, its treatment, and stress responses after stroke

Vanessa Juth,¹ E Alison Holman,¹ Michelle K Chan,¹ Steven C Cramer²

Juth V, et al. *J Investig Med* 2016;**64**:983-988.

Genetic Variation and Neuroplasticity: Role in Rehabilitation After Stroke

Jill Campbell Stewart, PT, PhD, and Steven C. Cramer, MD

(JNPT 2017;41: S17-S23)

Stroke, sTress, RehAbilitatiON, and Genetics Study

The STRONG Study
www.thestrongstudy.com

What is The STRONG Study?

STRONG Study will examine how stress and genetics can affect rehabilitation after stroke. The goal is to understand how to help people recover from stroke. Participation includes 3 visits over one year (the first one takes place in the hospital) plus a few phone calls.

To be part of this study, a person must:

- Have had a stroke in the past 18 days
- Be able to communicate in English

About Our Team

 Dr. Holman is a Professor of Nursing at the University of California, Irvine who does research on how people cope with stressful experiences.

 Dr. Cramer is a Professor of Neurology at the University of California, Irvine who does research on how people recover from stroke.

E. Alison Holman, PhD, FNP Steven C. Cramer, MD

Interested in learning more about this study?
Call us: (949) 824-7439
Email us: info@thestrongstudy.com

R01-NR015591 ; scramer@uci.edu

Why would clinicians study genetics?

Clinicians might study genetics in order to better

- Inform therapeutic decision-making, e.g., Rx choice or Rx dose; adverse event risk

Genetics and therapeutic decision-making

Cytochrome P450 enzymes metabolize many drugs; polymorphisms can alter drug levels, e.g., for clopidogrel, codeine, or azathioprine.

Vitamin K epoxide reductase complex reduces vitamin K; SNPs account for 25% of the variance in warfarin dosing.

Stevens Johnson syndrome from carbamazepine is substantially more common with even one copy of certain HLA alleles: B*1502 (Asian populations) and A*3101 (Europeans).

Why would clinicians study genetics?

Clinicians might study genetics in order to better

- Inform therapeutic decision-making, e.g., Rx choice or Rx dose; adverse event risk
- Understand biology and pathogenesis of disease
- Estimate individual risk, prognosis, tendencies
- Stratify enrollees in a clinical trial

Why would clinicians study genetics?

Clinicians might study genetics in order to better

- Inform therapeutic decision-making, e.g., Rx choice or Rx dose; adverse event risk
- Understand biology and pathogenesis of disease
- Estimate individual risk, prognosis, tendencies
- Stratify enrollees in a clinical trial

BDNF val⁶⁶met SNP: endophenotype
ApoE4 polymorphism: spontaneous stroke recovery
Dopamine polygene score: predicts motor learning, mood, impulsiveness, response to L-Dopa

Why would clinicians study genetics?

Stroke Recovery Genetics

Arne Lindgren, MD, PhD; Jane Maguire, RN, PhD


- Understand biology and pathogenesis of disease
- Estimate individual risk, prognosis, tendencies *Stroke. 2016;47:2427-2434*
- Stratify enrollees in a clinical trial

BDNF val⁶⁶met SNP: endophenotype
ApoE4 polymorphism: spontaneous stroke recovery
Dopamine polygene score: predicts motor learning, mood, impulsiveness, response to L-Dopa

Why would clinicians study genetics?


BDNF val⁶⁶met SNP: ← endophenotype
ApoE4 polymorphism: spontaneous stroke recovery
Dopamine polygene score: predicts motor learning, mood, impulsiveness, response to L-Dopa

Genetics of motor cortex plasticity









Kleim et al, 2006; *Nat Neurosci*

Genetics of motor cortex plasticity



Kleim et al, 2006; *Nat Neurosci*



Val/Val (n=26)

Motor cortex activation varied significantly per BDNF genotype.

But: differences in cortical function not related to baseline FM or to change in FM with therapy

- other compensatory process?
- wrong motor task during fMRI?
- endophenotype?

Val/Met (n=16)

Kim DY, Quinlan EB, Gramer R, Cramer SC. BDNF val⁶⁶met polymorphism is related to motor system function after stroke. *Phys Ther.* 2016;96:533-539

Endophenotype

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

Endophenotype

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

An endophenotype is an inherited trait marker, a component of a complex phenotype that is more directly related to the underlying genotype.

Endophenotype

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

An endophenotype is an inherited trait marker, a component of a complex phenotype that is more directly related to the underlying genotype.

Examples:

- Decreased pre-symptomatic hippocampal volume in certain genetic forms of Alzheimer's disease
- Increased error-related negativity (an EEG measure of cingulate activity following an error) in subjects with OCD
- Increased pre-symptomatic activation and connectivity in premotor cortex of certain genetic forms of Parkinson's disease

Imaging Endophenotypes of Stroke as a Target for Genetic Studies

Xueqiu Jian, PhD; Myriam Fornage, PhD

"Endophenotypes are typically quantitative and lie in the causal pathway to the disease but are closer to the gene action than the clinical phenotype..."

Variants in specific genes have been associated with several imaging endophenotypes of

- white matter hyperintensities
- covert brain infarcts by MRI
- Virchow-Robin spaces
- cerebral microbleeds
- carotid intima/media thickness
- atrial fibrillation

Stroke. 2018;49:1557-1562.

Genetic factors & brain atrophy after stroke

Genetic variation has been associated with differences in brain atrophy in many settings—is this true after stroke?

^^ Winstein et al. JAMA. 2016; 315:571-581.

Genetic factors & brain atrophy after stroke

Genetic variation has been associated with differences in brain atrophy in many settings—is this true after stroke?

Volume of the ventricles and the brain were measured in stroke survivors enrolled in ICARE trial.^{^^}

Brain atrophy expressed as the Ventricle-Brain Ratio (VBR).

VBR was then examined in relation to the two genotypes of interest, BDNF val⁶⁶met and ApoE ε4.

^{^^} Winstein et al. JAMA. 2016; 315:571-581.

Genetic factors & brain atrophy after stroke

n=127 (61 with MRI and 66 with a CT scan).

Scans acquired 5 ± 11 days post-stroke.

The BDNF val⁶⁶met genotype was present in 23/127 subjects; ApoE ε4, in 41/127; both were in HW equilibrium.

Mean ventricle volume=30.8 cc; brain volume=1,166 cc; and VBR=0.027

Genetic factors and brain atrophy after stroke

VBR as a function of
BDNF val⁶⁶met carrier status, p=0.014
ApoE ε4 carrier status, p=0.53

Genetic factors and brain atrophy after stroke

VBR as a function of
BDNF val⁶⁶met carrier status, p=0.014
ApoE ε4 carrier status, p=0.53

Mean VBR increases 1.97-fold (97%) when the BDNF val⁶⁶met polymorphism is present compared to absent.

Genetic factors and brain atrophy after stroke

VBR as a function of
BDNF val⁶⁶met carrier status, p=0.014
ApoE ε4 carrier status, p=0.53

Mean VBR increases 1.97-fold (97%) when the BDNF val⁶⁶met polymorphism is present compared to absent.

Mean VBR *not* associated with baseline behavior (WMFT, p=0.50) or its change over 12 months (p=0.47).

Genetic factors and brain atrophy after stroke

BDNF val⁶⁶met polymorphism assoc with 97% greater atrophy.

But BDNF val⁶⁶met not related to behavior at enrollment or 12 month change.

Suggests VBR is an endophenotype for val⁶⁶met status

Genetic factors and brain atrophy after stroke

BDNF val⁶⁶met polymorphism assoc with 97% greater atrophy.

But BDNF val⁶⁶met not related to behavior at enrollment or 12 month change.

Suggests VBR is an endophenotype for val⁶⁶met status.


VBR association with atrophy but not behavior might reflect short time interval examined, no measure of brain function (reserve); younger group enrolled, or that patients had mild-mod deficits.

Insights into biology of inter-subject differences in brain anatomy after stroke might inform restorative therapy and clinical trials.

BDNF val⁶⁶met SNP: endophenotype
 ApoE4 polymorphism: ← spontaneous stroke recovery
 Dopamine polygene score: predicts motor learning, mood, impulsiveness, response to L-Dopa

Genotype predicts gains in a clinical trial


Among 241 subjects in the GAIN trials
 % subjects with min/no disability (*modified Rankin Scale score 0-1*) was lower when the ApoE4 genotype present (*p = 0.01)



Cramer and Proccacio, Eur J Neurol. 2012; 19:718-724.

Genotype predicts gains in a clinical trial

Among 241 subjects in the GAIN trials
 % subjects with min/no disability (*modified Rankin Scale score 0-1*) was lower when the ApoE4 genotype present (*p = 0.01)



NINDS tPA trial; NEJM, 1995

Cramer and Proccacio, Eur J Neurol. 2012; 19:718-724.

Polygene score

Most genetic effects have RR in range of 1.1-1.4; effect of any single gene is generally small--ApoE is a major exception.

BDNF val⁶⁶met SNP: endophenotype
 ApoE4 polymorphism: spontaneous stroke recovery
 Dopamine polygene score: ← predicts motor learning, mood, impulsiveness, response to L-Dopa

Attia et al. JAMA 2009; Zheng et al. NEJM, 2008

Polygene score

Most genetic effects have RR in range of 1.1-1.4; effect of any single gene is generally small--ApoE is a major exception.

Thus interest in combining effect of many genes in polygenic models that assign points for the presence of risk alleles and calculates an overall risk of disease

Attia et al, JAMA 2009; Zheng et al, NEJM, 2008

Polygene score


Most genetic effects have RR in range of 1.1-1.4; effect of any single gene is generally small--ApoE is a major exception.

Thus interest in combining effect of many genes in polygenic models that assign points for the presence of risk alleles and calculates an overall risk of disease

Example: in a study of 5 SNPs associated with prostate cancer, risk of disease associated with increasing # risk alleles:
OR = 1.6 with risk allele at 1 SNP, OR = 4.5 with 4 risk alleles


Attia et al, JAMA 2009; Zheng et al, NEJM, 2008

The many proteins of the dopamine system



Nemoda et al. Neurosci Biobehav Rev 35:1665-1686, 2011

The many proteins of the dopamine system



Nemoda et al. Neurosci Biobehav Rev 35:1665-1686, 2011

Dopamine gene score

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Dopamine gene score

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

Dopamine gene score

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

OPEN ACCESS Freely available online **PLOS ONE**

Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa

Kristin M. Pearson-Fuhrhop¹, Brian Minton¹, Daniel Acevedo¹, Babak Shahbaba², Steven C. Cramer^{1,2,3}

¹ Department of Anatomy & Neurobiology, University of California Irvine, Irvine, California, United States of America, ² Department of Statistics, University of California Irvine, Irvine, California, United States of America, ³ Department of Neurology, University of California Irvine, Irvine, California, United States of America

Pearson-Fuhrhop et al PLOS-ONE 2013

OPEN ACCESS Freely available online **PLOS ONE**

Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa

Kristin M. Pearson-Fuhrhop¹, Brian Minton¹, Daniel Acevedo¹, Babak Shahbaba², Steven C. Cramer^{1,2,3}

¹ Department of Anatomy & Neurobiology, University of California Irvine, Irvine, California, United States of America, ² Department of Statistics, University of California Irvine, Irvine, California, United States of America, ³ Department of Neurology, University of California Irvine, Irvine, California, United States of America


Day 1 2 3 4 5 6 7 8 9 10

2 week washout

Legend

- TMS
- Baseline assessments
- Pill intake
- Skilled task practice

Pearson-Fuhrhop et al PLOS-ONE 2013



Genetic Variation in the Dopamine System Influences Intervention Outcome in Children with Cerebral Palsy

Rochellys Diaz Hejtz^a, Rita Almeida^a, Ann Christin Eliasson^b, Hans Forsberg^{b,c}

^a Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
^b Department of Women's and Children's Health, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden

AHA, changes

Dopamine score

Female Male

Hand training for 2hr/day x 2 mo in 33 children with cerebral palsy
 Gains in Assisting Hand Assessment scores varied by gene score

Diaz Hejtz et al, EBioMedicine 28 (2018) 162–167

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

Dopamine gene score


OPEN ACCESS Freely available online

PLOS ONE

Dopamine Genetic Risk Score Predicts Depressive Symptoms in Healthy Adults and Adults with Depression

Kristin M. Pearson-Fuhrhop^{1*}, Erin C. Dunn^{2,3,4,5}, Sarah Mortero¹, William J. Devan², Guido J. Falcone², Phil Lee^{2,3,4}, Avram J. Holmes^{2,5}, Marisa O. Hollinshead⁶, Joshua L. Roffman⁷, Jordan W. Smoller^{2,3,4}, Jonathan Rosand^{2,7,8}, Steven C. Cramer^{1,9}

Dopamine gene score and depression



Lower dopamine gene scores, i.e. lower dopamine neurotransmission, associated with greater depression scores.

Pearson-Fuhrhop et al PLOS-ONE 2014

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole

Hayley J. MacDonald¹, Cathy M. Stinear¹, April Ren¹, James P. Coxon², Justin Kao³, Lorraine Macdonald³, Barry Snow³, Steven C. Cramer⁴, and Winston D. Byblow¹

MacDonald et al, Journal of Cogn Neurosci. 2016; 28:909-919.

Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole

Hayley J. MacDonald¹, Cathy M. Stinear¹, April Ren¹, James P. Coxon², Justin Kao³, Lorraine Macdonald³, Barry Snow³, Steven C. Cramer⁴, and Winston D. Byblow¹

On placebo: lower dopamine gene scores (lower dopamine neurotransmission) associated with poorer impulse control.

On the dopamine agonist Ropinirole: lower dopamine gene scores showed improved response inhibition, while higher gene scores had trend towards worsened response inhibition.

MacDonald et al, Journal of Cogn Neurosci. 2016; 28:909-919.

Moving forward

On the one hand, large consortia, big questions, big data.
--Always with precise definitions and measures of phenotype

On the other hand, continue targeted studies of candidate genes.
--Esp those with highest therapeutic implications
--Need mechanistic insights, biomarkers that capture repair events of interest to optimize hypothesis testing

Stroke, sTress, RehabilItation, and Genetics Study



The STRONG Study
www.thestrongstudy.com

What is The STRONG Study?

STRONG Study will examine how stress and genetics can affect rehabilitation after stroke. The goal is to understand how to help people recover from stroke. Participation includes 3 visits over one year (the first one takes place in the hospital) plus a few phone calls.

To be part of this study, a person must:

- Have had a stroke in the past 18 days
- Be able to communicate in English

About Our Team

Dr. Holman is a Professor of Nursing at the University of California, Irvine who does research on how people cope with stressful experiences.

Dr. Cramer is a Professor of Neurology at the University of California, Irvine who does research on how people recover from stroke.

E. Alison Holman, PhD, FNP Steven C. Cramer, MD

Interested in learning more about this study?
Call us: (949) 824-7439
Email us: info@thestrongstudy.com

R01-NR015591 : scramer@uci.edu

Types of genetic variation

Stroke recovery, neurorehabilitation, and neural plasticity

Genetic variation in relation to recovery, rehab, and plasticity

Genomics as an Informational Tool in Neurorehabilitation

Steven C. Cramer, MD

Professor, Depts. Neurology, Anatomy & Neurobiology, and PM&R
Associate Director, Institute for Clinical & Translational Science
Co-PI, NIH StrokeNet (Recovery & Rehabilitation)

University of California, Irvine